Fifty percent clot lysis times of TAFI-deficient plasma supplemented with 179nM of a TAFI variant in the absence or presence of antibody
| . | No MA . | MA-Tom1-41B2* . | MA-TCK26D6 . |
|---|---|---|---|
| No addition | 24 ± 3 | 25 ± 1 | 25 ± 3 |
| TAFI-TI | 160 ± 24 | 195 ± 19 | 26 ± 4‡ |
| TAFI-TI-K133A | 39 ± 8† | 44 ± 7 | 36 ± 4 |
| . | No MA . | MA-Tom1-41B2* . | MA-TCK26D6 . |
|---|---|---|---|
| No addition | 24 ± 3 | 25 ± 1 | 25 ± 3 |
| TAFI-TI | 160 ± 24 | 195 ± 19 | 26 ± 4‡ |
| TAFI-TI-K133A | 39 ± 8† | 44 ± 7 | 36 ± 4 |
Data are minutes to 50% clot lysis (mean ± SD; n = 3). When indicated, human TAFI-TI or human TAFI-TI-K133A and/or MA-Tom1-41B2 or MA-TCK26D6 (both 1440nM) was added to the plasma. A tPA concentration of 120pM was used to initiate fibrinolysis.
MA-Tom1-41B2 is an irrelevant control antibody directed against tomato pectin methylesterase.20
P < .01 vs TAFI-TI.
P < .01 vs no MA.